What must sit behind a supplier’s TSE statement?
Consider an illustrative tender for an animal-derived collagen dressing. The supplier sends a signed letter saying the product is “TSE/BSE-free,” alongside a quality-system certificate. The purchasing question is whether the letter can be connected to the offered SKU, its raw materials and the evidence reviewed for the intended market. A signature establishes who made the statement; the supporting records establish what was assessed.
TSE means transmissible spongiform encephalopathy, a group of prion diseases; BSE is bovine spongiform encephalopathy. For the buyer, the important distinction is between a statement of absence and a documented assessment of risk. FDA’s guidance addresses animal components and manufacturing exposure, while the EU regulation requires a documented risk strategy for devices within its scope.1, 2
This guide is for distributors, hospital procurement teams and OEM quality staff deciding which documents to request and which gaps require escalation. It complements an ISO 10993 biological evaluation file review; animal-source pathogen risks need their own supporting evidence within the overall safety assessment. Neither a list of biocompatibility tests nor a supplier letter should be treated as a complete safety conclusion.4, 8
Which animal inputs belong in the inventory?
Ask the legal manufacturer to define the inventory boundary before requesting certificates. FDA’s guidance covers devices containing or exposed to animal-derived materials, including manufacturing reagents, with exclusions for IVDs and certain materials considered safe because of their manufacture. Its examples include tissue components, culture media and enzymes. A device that looks synthetic therefore still needs an evidence-based answer about relevant processing inputs.1
Record the material’s identity, species, tissue or derivative, role, supplier and document revision. Distinguish a retained component from a manufacturing aid, and distinguish animal origin from a generic chemical name. Do not infer that every stearate is animal-derived or that every polymer device is animal-free. If an input is claimed to be exempt or outside scope, request the basis for that conclusion rather than automatically demanding the full file.1, 6
| Input to screen | Question to send | Evidence to connect |
|---|---|---|
| Constituent tissue or derivative | Which species, tissue and source supply this component? | Material specification; source declaration; device/SKU reference. |
| Coating or impregnation | Does an animal derivative remain on a synthetic substrate? | Component specification and manufacturer’s applicable-rule assessment. |
| Manufacturing reagent | Was the device exposed to animal-derived enzymes, serum or media? | Process-input inventory and safety assessment of the relevant exposure. |
| Highly processed additive | What is its origin, and is an exception being relied on? | Supplier evidence and written applicability rationale for the specific jurisdiction. |
| Shared manufacturing environment | Which relevant cross-contamination risks were assessed? | Manufacturer’s risk-control summary and supporting audit access, where needed. |
Source: Editorial procurement framework; source references 1, 4, 6. Read with the scope notes in the text.
Keep the worksheet product-specific. A corporate declaration may cover only some sites, materials or product families. Ask whether the statement also covers subcontractors and upstream inputs, and how it is maintained when a raw-material supplier changes. If the manufacturer cannot answer the boundary question, collect that gap before deciding which additional documents are proportionate.
Four review layers for a sourcing file
The following framework organizes the buyer’s review. It does not mean that every distributor is entitled to every confidential technical record. Agree which evidence can be shared as a summary, reviewed under confidentiality, or made available to the relevant regulator or notified body. A useful summary identifies the underlying document and scope rather than merely repeating “compliant.”
Material inventory. Link each relevant animal input to the exact product configuration. Health Canada’s full-data guidance asks for material type, animal species, supplier details and other identifying information. FDA likewise recommends collection and documentation of source information. Use those references to ask focused questions, then let the applicable market assessment determine the required level of detail.1, 4
Origin and traceability. Connect source records to the material supplier and the device’s production records. Request the applicable country or zone, animal origin and residence information, relevant veterinary evidence and controls against cross-contamination. In the EU, Regulation 722/2012 makes source species, geographical origin and tissue characteristics part of the risk analysis. Avoid treating a country entry alone as proof that a particular material or lot is suitable.2, 4
Process and biological-safety evidence. Request the manufacturer’s assessment and the supporting validation or scientific rationale appropriate to the material and intended use. Specialist reviewers must judge whether the evidence supports the claimed scope. FDA and Health Canada distinguish pathogen risks and the evidence needed to address them; buyers should not infer a TSE conclusion from a routine sterility document.1, 4
Benefit and residual-risk justification. For EU devices within Regulation 722/2012, the manufacturer must justify animal-tissue use while considering clinical benefit, residual risk and suitable alternatives. That is an assessment of why the chosen material is acceptable for the device, rather than a universal demand to prove superiority over every synthetic product. Ask for the decision and its evidence boundary.2
| Layer | What the buyer records | Gap requiring escalation |
|---|---|---|
| Inventory | Covered SKU/version, animal inputs, suppliers and scope exclusions. | Letter covers only the finished ingredient, leaving relevant reagents unanswered. |
| Sourcing | Traceability references, geographical scope and applicable sourcing rationale. | Origin record cannot be connected to the supplied material or product version. |
| Process evidence | Technical report references, reviewer, scope and limitations. | Sterility certificate is offered as the only support for the TSE claim. |
| Justification | Applicable-market assessment of benefit, alternatives and residual risk. | Generic compliance statement with no identifiable device-level assessment. |
Source: Editorial procurement framework; source references 1, 2, 4. Read with the scope notes in the text.
How do the jurisdictional checks differ?
Start with the destination market and the actual device’s classification and authorization route. The documents below govern different questions. A recommendation for a manufacturer’s US submission is not automatically a purchasing obligation for a hospital, and a starting-material assessment is not authorization for a finished device.
United States. FDA’s animal-sources guidance was issued on 15 March 2019 and contains nonbinding recommendations. It covers animal materials in components and manufacturing exposure, subject to its stated exclusions. Its submission contexts include 510(k), De Novo, PMA and other applications. Ask the manufacturer how its source and manufacturing evidence supports the actual US device pathway; animal origin alone does not identify one universal pathway.1
European Union. The relevant MDR biological-origin provisions are in Annex I Section 13.2. Section 13.2(c) points to Regulation 722/2012 for devices within that regulation’s scope; Annex IX Section 5.3.2 also addresses the notified body’s application of those requirements. Regulation 722/2012 names bovine, ovine, caprine, deer, elk, mink and cats. It excludes certain rigorously processed tallow derivatives and devices with no human contact or only intact-skin contact.2, 3
Do not confuse that species list with MDR classification. Rule 18 addresses non-viable human or animal tissues, cells and derivatives more broadly, with an intact-skin-only exception for the animal-material devices described in the rule. MDCG’s April 2026 classification guidance also explains a trace-tallow-derivative qualification for Rule 18 and states that other biological-origin obligations can remain. Ask for the manufacturer’s written classification rationale rather than assigning Class III merely because an additive has animal ancestry.3, 10
Canada. Health Canada’s overview distinguishes full, reduced, limited and out-of-scope data situations. The full-data Class IV guidance requires ruminant materials within that framework to come from WOAH-recognized negligible-BSE-risk countries, including relevant bovine constituents in cell-culture media; it also specifies scrapie-free sourcing for sheep and goat materials. The overview includes other routes and material-specific conditions. Confirm the applicable category before copying the Class IV checklist onto every product.4, 8
China. NMPA Announcement 2024 No. 157, dated 31 December 2024, abolished YY/T 0771.1-2020 and YY/T 0771.2-2020. Shanghai’s regulator republishes that announcement. The official Hubei regulator page separately records publication of the animal-derived-device technical review guidance revised in 2017. These establish the repeal and the guidance’s historical publication; they do not establish a complete current standard or registration pathway for every device. Request the supplier’s current applicable-guidance and standards map for the particular Chinese filing and intended export market.5, 9
| Market | Question for the manufacturer | Avoid this inference |
|---|---|---|
| United States | How does the animal-source assessment support this device’s actual submission and quality records? | FDA guidance is a binding worldwide procurement checklist. |
| European Union | Why do Section 13.2, Rule 18 and the scope of 722/2012 apply or not apply to this device? | Outside 722/2012 means outside all MDR biological-safety requirements. |
| Canada | Which full, reduced or limited data category applies, and what sourcing conditions follow? | Every animal-derived product has the same Class IV data requirements. |
| China | What current instrument and edition supports each part of the offered dossier? | An abolished YY/T citation is sufficient current evidence, or repeal removes the safety assessment. |
Source: Editorial procurement framework; source references 1, 2, 3, 4, 5, 8, 9, 10. Read with the scope notes in the text.
This matrix is an intake tool, not a complete submission manual. Confirm conformity-assessment steps with the responsible regulatory team and, where applicable, the notified body. Neither a TSE letter nor a starting-material certificate establishes a promised review period or a finished device’s market status.
How should a buyer verify geographical sourcing?
WOAH publishes officially recognized negligible and controlled BSE risk statuses, including zones. Its lists are maintained through recognition and status-maintenance processes; recognized members submit annual reconfirmation by the end of November. Save the dated entry actually relied on, with the exact country or zone and the material’s relevant origin records. Do not substitute the exporter’s address for the donor animals’ origin.7
The geographical level matters. The current WOAH page lists some recognition by zone, including UK entries, rather than treating every entry as an identical whole-country statement. Record that distinction without turning a snapshot into a permanent “approved countries” list. Negligible BSE risk also does not mean absence of every animal pathogen or proof of safety for each material.7
For EU in-scope devices, Regulation 722/2012 also identifies the EU BSE country-classification decision as a reference and requires assessment of tissue risk. Ask the manufacturer to identify the applicable classification and version. A purchasing spreadsheet should not freeze a generic list of tissue categories or age thresholds and apply it to every species and sourcing route.2
Similarly, do not infer that hides, bone or any other named tissue are automatically acceptable merely from a broad risk label. The manufacturer’s assessment must address the actual material, sourcing controls, intended use and contamination pathways. Health Canada’s overview illustrates why materially different source and processing conditions can lead to different evidence categories.8
Why is a sterility certificate insufficient for the TSE claim?
FDA describes TSE agents as extremely resistant to traditional forms of disinfection and sterilization. Health Canada states that TSE-risk management relies largely on selective tissue sourcing and requires scientific support for any removal or inactivation claim. The buyer’s defensible conclusion is that a routine terminal-sterilization record cannot, on its own, substantiate the animal-source safety case.1, 4
Keep two document requests distinct: the evidence supporting the product’s sterile status, and the biological-safety assessment supporting the animal-derived inputs. Review the EO sterilization acceptance questions for the former. For the latter, ask a qualified specialist to assess whether the manufacturer’s cited evidence covers the actual materials and manufacturing process. A purchaser should not select or alter a processing method from an article.
There are also material-specific limits. Regulation 722/2012 provides for principal reliance on sourcing where an inactivation or elimination process would cause unacceptable device degradation. That requires a justified assessment within the relevant framework; it is not permission to omit the process question whenever a supplier prefers to rely on its sourcing letter.2
Which changes should reopen the sourcing review?
Write the change-notification expectations into the quality agreement. The events below are recommended review triggers. They do not all automatically cancel a product authorization or mandate a new regulatory submission. The manufacturer’s documented assessment and applicable regulatory requirements determine the consequence.
| Event | Evidence to revisit | Decision to record |
|---|---|---|
| Source country or zone changes | Origin records and destination-market sourcing assessment. | Whether the new source remains within the assessed scope. |
| Country or zone status changes | Current official status and manufacturer’s risk assessment. | Affected materials/lots and whether market-specific action is needed. |
| Material supplier or collection site changes | Traceability, inspection evidence and supplier qualification. | Whether previous evidence remains applicable. |
| Species, tissue or reagent changes | Inventory and biological-safety assessment. | Whether the offered device version is still covered. |
| Relevant process or shared-line changes | Manufacturer’s impact assessment and supporting technical references. | Whether additional review is required before accepting affected supply. |
Source: Editorial procurement framework; source references 1, 2, 4. Read with the scope notes in the text.
For devices within Regulation 722/2012, Annex I Section 2 addresses production and post-production information, including changes and renewed assessment when overall TSE risk increases. Preserve the distinction between identifying a change and determining that it increases risk. Ask who made the assessment, which lots and documents it covers, and whether notified-body or authority involvement was required.2
Agree a realistic notification period and an urgent route for unexpected events. This guide proposes no universal statutory notice period. The agreement should state who receives notices, how the buyer identifies affected stock, and how an unresolved evidence gap is escalated. Record temporary holds or additional review as procurement decisions with an owner, rather than claiming that a commercial checklist itself revokes regulatory clearance.
A sourcing-file request to send with an RFQ
Use this request as a discussion worksheet and adapt it to the market, device and confidentiality arrangements. It is not ready-to-sign contract language. The aim is a document index that a quality reviewer can follow, with unanswered questions visible before commercial acceptance.
- Identify the offer: legal manufacturer, site, product/SKU, configuration, intended use, target market and relevant authorization references.
- Define the animal-input scope: retained materials, coatings and relevant process inputs; identify exceptions and their rationale.
- Map the source: species, tissue or derivative, supplier and relevant country/zone of animal origin and residence.
- Index the records: identify supporting specifications, traceability and veterinary evidence applicable to this product and market.
- Summarize the safety assessment: identify technical reports, their scope, limitations and qualified review responsibility.
- Explain material selection: provide the applicable benefit and residual-risk rationale, including alternatives where required.
- Identify the current rules: list applicable guidance and standard editions; explain any reliance on an exception or reduced-data route.
- Arrange access: state what the buyer can receive and what needs controlled access by its reviewer, notified body or authority.
- Agree change control: define notification contacts, assessed change types and how affected product versions and lots will be identified.
A useful response has more than attachments. For each requested item, have the supplier record document reference and revision; covered device/material; scope limitation; access route; reviewer; open question; owner; and next review date. This turns “documents supplied” into a reviewable decision trail without demanding that procurement independently reproduce specialist safety work.
For example, if a dressing letter names bovine collagen but the inventory leaves an enzyme’s origin unanswered, mark the dossier as incomplete for that question. Ask the manufacturer to resolve the input and update the assessment or explain its exclusion. If the supplier identifies confidential evidence, agree controlled review. If it cannot identify supporting evidence at all, do not convert the absence into an approval merely because the quote is attractive.
Where VEMERIX fits—and where due diligence still begins
VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.
For a VEMERIX sourcing discussion, use the quality information as an introduction and request the available product-specific documentation for the device, market and material question you are evaluating. This guide makes no blanket animal-free or TSE-free claim about the portfolio. Such a statement would need evidence covering the relevant SKU, materials and manufacturing exposure.
Religious-compliance and pathogen-risk questions also need separate conclusions. The Indonesia device halal guide addresses a different market-specific decision. Do not substitute a halal certificate for the sourcing evidence needed to support biological safety, or assume this sourcing-file review establishes religious certification.
Frequently asked questions
Should we reject every one-page TSE/BSE statement?
No. It can be a useful summary if its scope, issuer and supporting references are clear. The gap is a statement that cannot be connected to the offered product and its evidence. Request proportionate supporting access before deciding whether qualification is complete.
Do reagents matter if they are absent from the finished device?
They can. FDA’s scope includes manufacturing exposure to animal materials, with specified exclusions. Ask the manufacturer to identify the relevant inputs and assess applicability, rather than treating removal from the final ingredient list as sufficient.1
Are porcine materials outside EU animal-origin controls?
They are outside the species list in Regulation 722/2012, but that does not remove MDR biological-origin requirements or settle Rule 18 classification. Keep the species-specific TSE regulation separate from the broader device assessment.2, 3, 10
Must every buyer demand negligible-BSE-risk sourcing?
Apply the destination framework. Health Canada’s full-data Class IV guidance specifies this for ruminant sources, while its overview includes other data categories and material-specific conditions. Do not impose that one rule as a universal worldwide requirement.4, 8
Does an old YY/T certificate settle a Chinese supplier’s current file?
No. The cited parts YY/T 0771.1-2020 and YY/T 0771.2-2020 were abolished by NMPA Announcement 2024 No. 157. Ask which current requirements and editions support the specific dossier; a historical document alone does not answer that question.5
What does a complete buyer review conclude?
It records the exact product and market reviewed, evidence inspected, limitations, open questions and the responsible quality decision. It supports procurement qualification without claiming to replace regulatory authorization or to prove zero biological risk.